FDA urgently authorizes screening-type medical AI products in response to new crown outbreaks

Clew, the AI predictive analytics platform, announced that its new Coronapneumonia Prediction Screening Tool for the ICU has been granted emergency use by the FDA. Founded in Israel in 2014, Clew Medical developed a system that analyzes medical information collected in the hospital’s intensive care unit, provides early warning of potentially life-threatening phenomena, and supports the decision-making process for the care of inpatients.

FDA urgently authorizes screening-type medical AI products in response to new crown outbreaks

In a normal hospital, the intensive care unit is usually the smallest department in the hospital, with only about 9 per cent of the beds, but it accounts for 31 per cent of the hospital’s budget, says co-founder Gal Salomon.

According to the company, health care providers can use Clew to help identify high-risk patients with respiratory failure or hemodynamic instability, a common complication of new coronary pneumonia.

“Ai-based algorithms are trained machine learning models that identify respiratory failure and hemodynamic instability several hours in advance,” says Clew. This allows health care providers to conduct additional assessments and, as far as possible, early intervention, planning, and resource management. “

Studies have shown that severe respiratory failure associated with bipulmonary pneumonia is one of the leading causes of the death rate of new coronary pneumonia. Early detection can allow for faster intervention and treatment, including through mechanical ventilation. It also allows the care team to develop strategies around resource allocation, which is critical to competency management.

FDA urgently authorizes screening-type medical AI products in response to new crown outbreaks

According to the statement, Clew’s artificial intelligence products have been trained on nearly 100,000 ICU patients and were developed for use in local ICUs and remote ICUs. In addition, the product integrates workflow and resource decisions for both local and remote teams.

ClewICU is one of several EUAs tools released by the FDA to address new coronapneumonia, including in vitro diagnostic tools, remote patient monitoring devices, respiratory aids and non-surgical masks, and is by far the only authorized predictive screening tool.

During the outbreak of new coronapneumonia in the United States, many researchers developed artificial intelligence-based tools to try to help detect symptoms in patients with new coronary pneumonia.

In a study published last month in Nature Medicine, scientists at Mount Sinai Health System combined artificial intelligence with imaging and clinical data to quickly diagnose patients with COVID-19.

Developers such as behold.ai, Thirona and Delft Imaging have also released software that can use AI to quickly detect new coronal pneumonia in patients’ X-rays.

At the same time, modeling tools such as Health Catalyst can use existing patient data to predict hospital capacity and resources to prevent a run on medical resources.

“Clew’s ICU platform is designed to enable healthcare providers to monitor and predict risk levels for all patients in real time, enabling informed decisions about clinical resource allocation and ensuring timely, proactive and efficient care for patients,” Gal Salomon, Ceo of Clew, said in a statement. “

He added, “Medical institutions and health care providers need more than simple analysis.” The system also needs to be integrated into the work process eswork of the healthcare organization to provide easy-to-use and viable data. “